US Bancorp DE Lowers Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

US Bancorp DE cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 86.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,223 shares of the biopharmaceutical company's stock after selling 39,150 shares during the period. US Bancorp DE's holdings in Catalyst Pharmaceuticals were worth $130,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. abrdn plc acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $10,115,000. Jane Street Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock worth $7,990,000 after purchasing an additional 285,564 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $4,936,000. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after buying an additional 151,495 shares during the last quarter. Finally, Barclays PLC increased its stake in Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after buying an additional 140,129 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

CPRX has been the subject of several recent analyst reports. Bank of America restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Finally, Stephens reaffirmed an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $32.50.

Catalyst Pharmaceuticals Trading Up 2.3 %

Shares of NASDAQ:CPRX traded up $0.52 during midday trading on Thursday, hitting $23.12. 676,851 shares of the stock were exchanged, compared to its average volume of 1,042,942. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $24.64. The company has a 50 day moving average price of $22.34 and a 200-day moving average price of $21.57. The stock has a market cap of $2.81 billion, a P/E ratio of 19.54, a PEG ratio of 3.31 and a beta of 0.84.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.